T1	Participants 48 65	advanced melanoma
T2	Participants 322 375	in previously treated patients with advanced melanoma
T3	Participants 470 517	enrolled patients without regard to HLA subtype
T4	Participants 546 616	phase III trial was restricted to class-I HLA-A*0201-positive patients
T5	Participants 752 808	phase II trials and was available for 93.5% of patients.
T6	Participants 932 999	pretreated patients randomized to 0.3, 3, or 10 mg/kg ipilimumab in
